Bashir Mahmoud Rezk Atteia, PhD


Associate Professor
Department of Natural Sciences
Southern University at New Orleans
6400 Press Drive
New Orleans, LA. 70126, USA

Biography

Dr. Atteia attained his BSc Degree from the Faculty of Science, Cairo University in May 1995. He obtained his Master Degree in comparative Physiology and cancer biology/ Experimental oncology from Cairo University in 2000. In May 2001, he awarded a prestigious scholarship to join the PhD program in Human Toxicology from the Netherlands Foundation on Prevention and Treatment of Chronic Diseases (Faculty of Medicine, Maastricht University, the Netherlands). In December 2004, Dr. Atteia obtained his PhD in Biomedical Sciences/Human Toxicology from Maastricht University, The Netherlands. In 2005 Dr. Atteia was recruited by the Department of Pharmacology and Experimental Therapeutics of the LSU Health Sciences Centre (New Orleans, LA). After his tenure at LSU Health Sciences Centre, he joined Heart and Vascular Institute at Tulane University (New Orleans, LA). Dr. Atteia awarded several grants from Sexual Medicine Society of North America and Louisiana Biomedical Research Network/IDEA Networks of Biomedical Research Excellence (LBRN/ INBRE).

Research Interest

His research interest includes: Experimental Therapeutics for Erectile Dysfunction. Mechanism of actions and effects of several drugs and compounds including, but not limited to, Folic acid, Lipoic acid, 4-Hydroxy-2,5,6-triaminopyrimidine, Sildenafil, and Tadalafil, on vesicular transport and exosomal micro RNA in human penile smooth muscle cells. Other research areas; Men infertility, Muscle atrophy, Skeletal Muscle Stem Cells and Bone Marrow transplantations, Pharmacology and Experimental Therapeutics (Cardiovascular diseases), Human Toxicology, Chemistry of Antioxidants and their metabolites, Experimental oncology and cancer drug screening, Cancer drugs monitoring, Tracking of cardiac mitochondrial β-oxidation pathways in health and diseases using radioactive 14C

Scientific Activities

AWARDS

• Awarded Presidential Scientific Prize, Arab Republic of Egypt (1998)
• Awarded the Prize of Academy of Scientific Research and Technology in the development of the Egyptian villages (1993)
• Awarded the Cairo University Prize in the pollution of the Nile River: Problem and Solution (1994)
• Awarded Scientific prize of Southern Society for Clinical Investigation and International Academy of Cardiovascular Sciences (2009)
• A journalist in the Egyptian Press (1997)
• Attended an intensive training program in the addiction and clinical toxicology as a lecturer and a student. Faculty of Medicine, Cairo University, Cairo, Egypt (2005)
• Attended the conference of the development of the Scientific Research in Egypt (2005)
• Attended American Heart Association meeting 2009. Ernest N. Morial Convention Center – New Orleans, Nov 8-12, (2008)
• Consultant for a funded grant on a selective anticancer agent; alpha-tocopheryl succinate, Pharmacology and Experimental Oncology Unit, Department of Cancer Biology National Cancer Institute, Cairo University, Egypt (2006-present)

MEMBERSHIPS

• American Heart Association (AHA)
• American Society of Nutrition (ASN)
• American Association of Anatomists (AAA)
• American Federation for Medical Research/Southern Society for Clinical Investigation (AFMR/SCCI)
• Society for Free Radical Biology and Medicine
• American Society of Andrology
• Sexual Medicine Society of North America

Publications

1. Zakaria Y. Elmageed A, Yang Y, et al. Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells. 2014; 32(4): 983-997. doi: 10.1002/stem.1619
2. Gur S, Sikka SC, Mageed AAB, et al. Imatinib Mesylate (Gleevec) Induces Human Corpus Cavernosum Relaxation by Inhibiting Receptor Tyrosine Kinases (RTKs): Identification of New RTK Targets. Urology. 2013; 82(3): 745.e11-e16. doi: 10.1016/j. urology
3. Yoshida T, Galvez S, Tiwari S, et al. Angiotensin II Inhibits Satellite Cell Proliferation and Prevents Skeletal Muscle Regeneration. J Biol Chem. 2013; 288(33): 23823-23832. doi: 10.1074/jbc
4. Naura AS, Kim H, Ju J, et al. Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-NF-κB-GATA-3-IL-4 axis without a prominent effect on PARP. J Biol Chem. 2013; 288(3): 1458-1468. doi: 10.1074/jbc.M112.419580
5. Bashir MR, Yoshida T, Prieto LS, Higashi Y, Sukhanov S, Delafontaine P. Angiotensin II infusion induces marked diaphragmatic skeletal muscle atrophy. PLoS One. 2012; 7(1): e30276. doi: 10.1371/journal.pone.0030276
6. Laura C, Prieto S, Sukhanov S, et al. Angiotensin II induced catabolic effect and muscle atrophy are redox dependent. Biochemical and Biophysical Research Communications. 2011; 409(2): 217-221. doi: 10.1016/j.bbrc.2011.04.122
7. Chetan PH, Feng Y, Amarjit S, et al. Protective Effects of PARP-1 Deficiency on Dyslipidemia-Induced Autonomic and Vascular Dysfunction in ApoE–/– mice: Role of eNOS Activation and Oxidative Stress. PLoS One. 2009; 4(10): e7430. doi: 10.1371/journal.pone.0007430
8. Zerfaoui M, Naura AS, Errami Y, et al. Effects of PARP-1–deficiency on airway inflammatory cell recruitment in response to LPS or TNF-α: Differential effects on CXCR2 ligands and Duffy antigen receptor for chemokines. J Leukoc Biol. 2009. doi: 10.1189/jlb.0309183
9. Naura A, Datta R, Hans C, et al. Reciprocal regulation between inducible NO synthase and Poly (ADP-ribose)polymerase during allergen-induced airway inflammation: requirement versus dispensability. Eur Respir J. 2009; 33(2): 252-262. doi: 10.1183/09031936.00089008
10. Su J, Lucchesi PA, Suzuki Y, et al. Role of Advanced Glycation End Products with Oxidative Stress in Resistance Artery Dysfunction in Type 2 Diabetic mice. Arterioscler Thromb Vasc Biol. 2008; 28(8): 1432-1438. doi: 10.1161/ATVBAHA.108.167205
11. Rezk BM, Vijgh VDWJ, Bast A, Haenen GRMM. Alpha-tocopheryl phosphate is a novel apoptotic agent. Front Biosci. 2007; 12: 2013-2019.
12. Rocic P, Rezk B, Lucchesi PA. PPAR-gamma agonists decrease hyperhomcysteinemia and cardiac dysfunction: new hope for ailing diabetic hearts?. Am J Physiol Heart Circ Physiol. 2006; 291(1): H26-H28. doi: 10.1152/ajpheart.00277.2006
13. Rezk BM, Haenen GRMM, Vijgh VDWJF, Bast A. The extraordinary antioxidant activity of vitamin E phosphate. Biochim Biophys Acta. 2004; 1683: 16-21. doi: 10.1016/j.bbalip.2004.03.005
14. Rezk BM, Haenen GRMM, Vijgh VDWJF, Bast A. Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage. J Biol Chem. 2004; 279: 9693-9697. doi: 10.1074/jbc.M312289200
15. Rezk BM, Haenen GRMM, Vijgh VDWJF, Bast A. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore. FEBS Lett. 2003; 555: 601-605. doi: 10.1016/S0014-5793(03)01358-9
16. Rezk BM, Haenen GRMM, Vijgh VDWJF, Bast A. The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochem Biophys Res Commun. 2002; 295: 9-13. doi: 10.1016/S0006-291X(02)00618-6
17. Ahmed SMM, Shouman SA, Rezk BM, Khalifa MH, Osman AM, El-Merzabani MM. Propionyl-L-carnitine as potential protective agent against adriamycin-induced impairment of fatty acid beta-oxidation in isolated heart mitochondria. Pharmacol Res. 2000; 4: 143-150. doi: 10.1006/phrs.1999.0583
18. Rezk BM, van der Vijgh WJF, Bast A, Haenen GRMM. Toxicity of the antioxidants. Toxicol Forensic Med Open J. 2015; 1(1): e3-e4. doi:10.17140/TFMOJ-1_e002
19. Rezk BM, Khedr MEY, Sikka SC, Hellstrom WJG, Abdel-Mageed AB. Electronic cigarettes: Toxicity and addiction. Toxicol Forensic Med Open J. 2016; 1(2): e16-e18. doi:10.17140/TFMOJ-1-e007

BOOK CHAPTER

1. Rezk BM, Sikka S. Developmental and reproductive disorders: role of endocrine disruptors in testicular toxicity. Reproductive and developmental toxicology. San Diego: Academic Press, 2011: 903-912. doi: 10.1016/B978-0-12-382032-7.10069-4